Requirement of BMP-2-induced Phosphatidylinositol 3-kinase and Akt Serine/threonine Kinase in Osteoblast Differentiation and Smad-dependent BMP-2 Gene Transcription
Overview
Authors
Affiliations
The mechanism by which bone morphogenetic protein-2 (BMP-2) induces osteoblast differentiation is not precisely known. We investigated the involvement of the phosphatidylinositol (PI) 3-kinase/Akt signal transduction pathway in modulation of this process. BMP-2 stimulated PI 3-kinase activity in osteogenic cells. Inhibition of PI 3-kinase activity with the specific inhibitor Ly-294002 prevented BMP-2-induced alkaline phosphatase, an early marker of osteoblast differentiation. Expression of dominant-negative PI 3-kinase also abolished osteoblastic induction of alkaline phosphatase in response to BMP-2, confirming the involvement of this lipid kinase in this process. BMP-2 stimulated Akt serine/threonine kinase activity in a PI 3-kinase-dependent manner in osteoblast precursor cells. Inhibition of Akt activity by a dominant-negative mutant of Akt blocked BMP-2-induced osteoblastic alkaline phosphatase activity. BMP-2 stimulates its own expression during osteoblast differentiation. Expression of dominant-negative PI 3-kinase or dominant-negative Akt inhibited BMP-2-induced BMP-2 transcription. Because all the known biological activities of BMP-2 are mediated by transcription via BMP-specific Smad proteins, we investigated the involvement of PI 3-kinase in Smad-dependent BMP-2 transcription. Smad5 stimulated BMP-2 transcription independent of addition of the ligand. Dominant-negative PI 3-kinase or dominant-negative Akt inhibited Smad5-dependent transcription of BMP-2. Furthermore dominant-negative Akt inhibited translocation of BMP-specific Smads into nucleus. Together these data provide the first evidence that activation of BMP receptor serine/threonine kinase stimulates the PI 3 kinase/Akt pathway and define a role for this signal transduction pathway in BMP-specific Smad function during osteoblast differentiation.
Huang X, Peng Y, Lu L, Gao L, Wu S, Lu J Drug Des Devel Ther. 2024; 18:4119-4134.
PMID: 39296670 PMC: 11410030. DOI: 10.2147/DDDT.S457100.
FOXO1 regulates RUNX2 ubiquitination through SMURF2 in calcific aortic valve disease.
Jiang C, Yao D, Liu Z, Zheng Y, Chen M, Yim W Redox Biol. 2024; 73:103215.
PMID: 38810422 PMC: 11167395. DOI: 10.1016/j.redox.2024.103215.
Cao S, Wei Y, Yue Y, Xiong A, Zeng H J Inflamm Res. 2024; 17:2479-2498.
PMID: 38681072 PMC: 11055561. DOI: 10.2147/JIR.S462722.
Yun H, Kim E, Kwon Y, Park K Pharmaceutics. 2024; 16(4).
PMID: 38675146 PMC: 11054936. DOI: 10.3390/pharmaceutics16040485.
Zhu N, Hou J, Si J, Yang N, Chen B, Wei X Mol Biol Rep. 2024; 51(1):530.
PMID: 38637425 DOI: 10.1007/s11033-024-09406-8.